Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019.

ABSTRACT:

Background

Biomarker-guided therapy could improve management of inpatients with coronavirus disease 2019 (COVID-19). Although some results indicate that antibody tests are prognostic, little is known about patient management using point-of-care (POC) antibody tests.

Methods

COVID-19 inpatients were recruited to evaluate 2 POC tests: LumiraDx and RightSign. Ease of use data were collected. Blood was also collected for centralized testing using an established antibody assay (GenScript cPass). A nested case-control study assessed if POC tests conducted on stored specimens were predictive of time to sustained recovery, mortality, and a composite safety outcome.

Results

While both POC tests exhibited moderate agreement with the GenScript assay (both agreeing with 89% of an

SUBMITTER: Reilly C 

PROVIDER: S-EPMC11911911 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature